Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A

cha-ching

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. Photo via Getty Images

An emerging biotech company in Houston has closed its series A with outsized success.

March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The company has now raised more than $51 million in total.

Last year, March Biosciences announced its strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience. CEO Sarah Hein met her co-founder, Max Mamonkin, at the TMC Accelerator for Cancer Therapeutics. Along with fellow co-founder Malcolm Brenner, March Biosciences launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital and Texas Children’s Hospital). Its goal is to fight cancers that have been unresponsive to existing immunotherapies using its lead asset, MB-105.

An autologous CD5-targeted CAR-T cell therapy, MB-105 is currently in phase-1 trials in patients with refractory T-cell lymphoma and leukemia. The treatment is showing signs of being both safe and effective, meriting a phase-2 trial that will begin early next year. The funds raised from the series A will help to finance the Phase 2 clinical development of MB-105 to expand on the existing data with optimized manufacturing processes.

“This oversubscribed financing enables us to advance our first-in-class CAR-T therapy, MB-105, into a Phase 2 trial for T-cell lymphoma – an indication with an exceptionally poor prognosis and few treatment options,” says Hein. “With the support and confidence of our investors, we are not only advancing our lead program but also expanding our pipeline, underscoring our commitment to delivering best-in-class therapies to patients that can change the treatment paradigm for these challenging cancers.”

But that’s not the only exciting news that Hein and her associates have to report. March Biosciences has recently partnered with cell therapy venture studio, Volnay Therapeutics. Led by highly experienced cell therapy development veterans, the March Biosciences team will work to develop a scalable manufacturing process for MB-105 that will lead to commercialization. Volnay co-founder and CEO Stefan Wildt, who held key R&D leadership positions in cell and gene therapy units at Novartis and Takeda, has also joined the board of March Biosciences. The board of directors is also welcoming Cassidy Blundell of Mission BioCapital and Owen Smith of 4BIO Capital.

“The team at March Biosciences is leveraging powerful science and promising clinical data to tackle cancers with significant unmet need,” says Blundell, a partner at Mission BioCapital. “We're excited to support their journey and believe their focused approach with MB-105 could lead to significant breakthroughs in the CAR-T space.”

The Houston-born company, which is a finalist for the 2024 Houston Innovation Awards, continues to accelerate quickly, in part thanks to its home base. After all, existing local investors like TMC Venture Fund also participated in the new raise. As Hein said last year, “Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

From Your Site Articles
CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

OncoResponse in partnership with MD Anderson Cancer Center received a portion of $73 million the Cancer Prevention and Research Institute of Texas has doled out this spring. Photo via oncoresponse.com

Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization

CPRIT funding spotted

A biotech company has landed a more than $13 million grant from the Cancer Prevention and Research Institute of Texas.

The nearly $13.3 million grant given to OncoResponse — which is relocating from Seattle to Houston, according to CPRIT's news release — will help the company develop fully human monoclonal antibodies for treatment of cancer that otherwise would not respond to immunotherapy. OncoResponse already has a partnership with MD Anderson Cancer Center, which is one of the company’s investors.

“We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502. We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies derived from clues of Elite Responders,” says Clifford Stocks, CEO of OncoResponse, in a news release.

Aside from the grant, OncoResponse just hauled in $14 million from existing investors in a round led by RiverVest Venture Partners. Other participants in the series D round include Venture Partners, Canaan Partners, 3B Future Health Fund, Bering Capital, Takeda Ventures, and InterVest Capital Partners.

To date, OncoResponse has raised more than $180 million, according to market research company CB Insights.

A representative of OncoResponse couldn’t be reached for comment about the company’s relocation to Houston.

MD Anderson and Seattle-based Theraclone Sciences launched OncoResponse in 2015. Rice University was among the inaugural investors.

OncoResponse’s OR2805 immunotherapy product is being evaluated in a Phase 1 clinical trial. It’s the company’s leading immunotherapy candidate. OncoResponse is also working on OR502, an antibody being prepared for investigational and clinical studies.

“The modern treatment of cancer activates the body’s own immune system to attack cancer,” OncoResponse says in a summary posted on the website of the Cancer Prevention and Research Institute of Texas (CPRIT).

“These treatments, called immunotherapy, may not be successful if the cancer can recruit bad-acting cells, such as tumor associated macrophages, or TAMs, that create barriers preventing immunotherapies from activating the body’s own defenses against the cancer. To find drugs that may help counteract these TAMs, OncoResponse looked to patients who had responded very well to immunotherapy to see if their bodies made factors to block TAMs and helped them fight their cancers.”

OncoResponse’s OR502 prevents TAMs from shutting down the body’s response to cancer, thus restoring tumor-killing immune activity, CPRIT explains.

In addition to OncoResponse, recent CPRIT grant recipients from the Houston area are:

  • Houston-based 7 Hills Pharma, $13,439,001. The company is working on immunotherapies for treatment of cancer and prevention of infectious diseases.
  • Houston-based Allterum Therapeutics, $11,721,150. The company is coming up with an antibody for treatment of patients with acute lymphoblastic leukemia. This type of cancer affects blood and bone marrow.
  • Houston-based Cell Therapy Manufacturing Center, $9.1 million. The center is a joint venture between National Resilience and MD Anderson Cancer Center that is developing cell therapy manufacturing technologies to support biotech partnerships.
  • Houston-based Pulmotect, $8,851,165. The company’s PUL-042 product is aimed at treating and preventing respiratory complications in cancer patients.
  • Cancer researcher Michael King, $6 million. The grant helped lure King to Rice from Nashville’s Vanderbilt University, where he’s been the chair of biomedical engineering. King’s lab at Vanderbilt has been testing therapies for metastatic breast cancer and prostate cancer.
  • Missouri City-based OmniNano Pharmaceuticals, $2,711,437. The pharmatech company is working on two drugs for treatment of solid tumors in patients with pancreatic cancer.

“Texas is unique because of CPRIT’s ability to invest in cutting-edge research when private capital is scarce. This is yet another way Texas is leading the nation in the fight against cancer,” Wayne Roberts, CEO of CPRIT, says in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

11 can't-miss Houston business and innovation events for August

where to be

Editor's note: The tech event scene is heating up in August. From insightful talks to a young professionals summit, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Aug. 5 – Tech and Tequila Talk

Hear from guest speaker David Cohen, founder & CEO of Dallas-based Superposition, at the latest installment of Tech and Tequila Talk. The event will focus on breaking down ambiguity in data and AI projects through collaborative workshops.

This event takes place Tuesday, Aug. 5, from 5-7 p.m. at the Ion. Click here to register.

Aug. 11-16 – Black is Tech Week

Black is Tech Week will bring events for tech professionals, entrepreneurs and students to Houston through summits, career fairs, networking events and more. The event will feature speakers from Amazon, Microsoft, Google and many other companies.

This event begins Monday, Aug. 1. Find more information here.

Aug. 12 – NASA Stories at the Ion

Head to the Ion for the new morning series spotlighting the human side of space exploration. Each session will feature personal and powerful stories from astronauts and key NASA personnel. Anthony Vareha, NASA Flight Director and Flight Operations Directorate, whose primary duty is the safe operation of the International Space Station will speak this month.

This event begins Tuesday, Aug. 12, from 8:30-10 a.m. Find more information here.

Aug. 14 – Pickle Lab’s One-Year Anniversary Celebration

Enjoy an afternoon of open-play pickleball, beats by a live DJ, raffle giveaways and free swag at the first anniversary celebration of Pickle Lab in the Ion District. WonderPops will provide complimentary pops while supplies last, and Second Draught will serve each guest a free beverage.

This event takes place Thursday, Aug. 14, from 4-7 p.m. RSVP here.

Aug 19 – Navigating the Economy: Insights from Darren King

Darren King, chief investment officer of Moody Bank, will share his expert insights on the state of the economy and its impact on Houston’s future. Gain a deeper understanding of market trends, economic shifts and what they mean for businesses and individuals in the city.

This event takes place Tuesday, Aug. 19, from 11:30-1 p.m. RSVP here.

Aug. 21 – Transition on Tap

Greentown Labs’ signature networking event returns in August to foster conversations and connections within Houston's climate and energy transition ecosystem. Entrepreneurs, investors, students, philanthropists and more are invited to attend, meet colleagues, discuss solutions and engage with the growing community.

This event takes place Thursday, Aug. 21, at 5:30 p.m. at Greentown Labs. Click here to register.

Aug. 22 – Determined to Lead Women Lunch: Investing Through Market Cycles with Ellen Wilkirson

EnergyTech Nexus hosts a monthly Determined to Lead Women’s Lunch as part of its ongoing efforts to create safe spaces for women leaders in the energy transition to connect, learn and lead. The August session features Ellen Wilkirson, principal at Rev Innovations. With deep experience across traditional and transition energy sectors, Wilkirson will share how she’s approached investing through multiple market and commodity cycles and what it means to be a clean energy investor in today’s evolving landscape.

This event takes place Friday, Aug. 22, at 1 p.m. Click here to register.

Aug. 26 – Software Day at the Ion: Positioning your Startup to Capitalize on Market Trends

Software Day is a monthly series driving the support, inspiration and connections needed to help startups on their path to rapid, sustainable growth. Each month, Software Day will include office hours (by application), a keynote session and networking. This month’s panel discussion will feature Remington Tonar, co-founder of Cart.com, and Josh Teekell, founder of SmartAC.com.

This event takes place Tuesday, Aug. 26, from 3:30-7 p.m. Click here to register.

Aug. 27 – Future of Flight: Inside Venus Aerospace with Founder Sassie Duggleby

Join EO Houston for an exclusive, behind-the-scenes conversation with Sassie Duggleby, co-founder and CEO of Venus Aerospace, a Houston-based company pioneering breakthrough propulsion systems for hypersonic and space applications.

This event takes place Wednesday, Aug. 27, at 10 a.m. at Venus Aerospace. It is open to EO members and partners only. Click here to register.

Aug. 27 – The Future of American Science: A Conversation With US Rep. Brian Babin

U.S. Rep. Dr. Brian Babin and Paul Cherukuri, vice president of innovation at Rice University, will discuss how the United States remains at the forefront of space exploration, emerging technologies and scientific advancement, as well as what's next and what's at stake for the future of science policy.

This event takes place Wednesday, Aug. 27, from 3-4 p.m. at James A. Baker III Hall on Rice University's campus. Click here to register.

Aug. 28 – HYPE Summit

The third annual Houston Young Professionals and Entrepreneurs (HYPE) Summit is a day-long conference featuring panel discussions with business and thought leaders, workshop-style breakout sessions and networking opportunities. This year's event—under the theme Step Into the Spotlight—will feature speakers from First Bight Ventures, Bot Auto, Regions Bank, Lopez Negrete Communications and Umbrage.

This event takes place Thursday, Aug. 28, from 8:30 a.m.-5:30 p.m. at The Hobby Center for the Performing Arts. Click here to register.

Houston's 13 best midsize companies and more innovation news to know

Trending Topics

Editor's note: The top innovation news from the second half of the month includes new leaders at innovative Houston organizations and a ranking of the best midsize businesses from Time. Here are the five most-read InnovationMap stories from July 15-31, 2025:

13 Houston businesses appear on Time's best midsize companies of 2025

13 Houston-area businesses ranked on Time magazine's best midsize companies list. Photo via Getty Images

Houston-based engineering firm KBR tops the list of Texas businesses that appear on Time magazine and Statista’s new ranking of the country’s best midsize companies. KBR holds down the No. 30 spot, earning a score of 91.53 out of 100. Twelve other Houston-based companies landed on the list. Continue reading.

Digital Health Institute's new exec director aims to lead innovation and commercialization efforts

Pothik Chatterjee was named executive director of Rice University's and Houston Methodist's Digital Health Institute, effective May 1. Photo courtesy Rice University.

Though our existences have become deeply entangled with technology, our health has been slower to catch up. The creation late last year of the Digital Health Institute was a major step into the future for both Rice University and Houston Methodist, for whom the institute is a joint venture. The latest news for the Digital Health Institute is the appointment of Pothik Chatterjee to the role of executive director. Continue reading.

Houston hardtech accelerator names 8 scientists to 2025 cohort

Activate Houston has named eight fellows to its 2025 cohort. Photo courtesy the Ion.

National hardtech-focused organization Activate has named its 2025 cohort of scientists, which includes new members to Activate Houston. The Houston hub was introduced last year, and joins others in Boston, New York, and Berkley, California, where Activate is headquartered. Collectively, the 2025 Activate Fellowship consists of 47 scientists and engineers from nine U.S. states. Continue reading.

Rice biotech accelerator appoints 2 leading researchers to team

The Rice Biotech Launch Pad has named two bioengineering professors to its leadership team. Photo courtesy Rice University.

The Rice Biotech Launch Pad, which is focused on expediting the translation of Rice University’s health and medical technology discoveries into cures, has named Amanda Nash and Kelsey L. Swingle to its leadership team. Both are assistant professors in Rice’s Department of Bioengineering and will bring “valuable perspective” to the Houston-based accelerator. Continue reading.

Innovation Labs @ TMC set to launch for early-stage life science startups

Innovation Labs @ TMC will open next year at the TMC Innovation Factory. Photo courtesy JLABS.

The Texas Medical Center will launch its new Innovation Labs @ TMC in January 2026 to better support life science startups working within the innovation hub. The 34,000-square-foot space, located in the TMC Innovation Factory will feature labs and life science offices and will be managed by TMC. Continue reading.

Intuitive Machines lands $9.8M to complete orbital transfer vehicle

space funding

Houston-based Intuitive Machines, which rang the NASDAQ opening bell July 31, has secured a $9.8 million Phase Two government contract for its orbital transfer vehicle.

The contract will push the project through its Critical Design Review phase, which is the final engineering milestone before manufacturing can begin, according to a news release from the company.

Intuitive Machine's orbital transfer vehicle (OTV) is designed to transfer payloads between Earth's orbit and the Moon and is built around the company's Nova-C lander, which has been a part of two successful lunar missions.

“Our OTV is a direct evolution of our lunar surface delivery missions—positioning us to expand into the rapidly growing market for in-space logistics,” Steve Altemus, Intuitive Machines CEO, said in the release. “We’re leveraging our flight-proven technology to operate a mission-ready service that delivers customer payloads across orbits—from Earth to the Moon and beyond.”

The company says the fast, flexible vehicle could be used for orbital servicing, logistics and communications in medium earth orbit, low lunar orbit and a variety of other destinations.

Intuitive Machines expects to begin manufacturing and flight integration as soon as 2026, once the design review is completed.

The non-NASA contract is for an undisclosed government customer, which Intuitive Machines says reinforces its "strategic move to diversify its customer base and deliver orbital capabilities that span commercial, civil, and national security space operations."

The company has received millions from NASA for its lunar rover, lunar lander, science and technology payloads, and communications and navigation services over the years. It also recently landed up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab from Texas's Space Exploration and Research Fund.

Earlier this month, the City of Houston agreed to add three acres of commercial space for Intuitive Machines at the Houston Spaceport at Ellington Airport. Read more here.

View All Listings